Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions - Wikidata - wikimedia - TriplyDB

Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions

Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions

http://www.wikidata.org/entity/Q34568606

about

Epigenomics of leukemia: from mechanisms to therapeutic applications Chemopreventive potential of flavonoids in oral squamous cell carcinoma in human studies Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases Notes from the field: "green" chemoprevention as frugal medicine Oral premalignancy: the roles of early detection and chemoprevention Cancer Preventive Activities of Tea Catechins Biophysical Approach to Mechanisms of Cancer Prevention and Treatment with Green Tea Catechins Topical polyethylene glycol as a novel chemopreventive agent for oral cancer via targeting of epidermal growth factor response Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability Liver-related safety assessment of green tea extracts in humans: a systematic review of randomized controlled trials Tea consumption and risk of head and neck cancer.Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components.Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53 Green tea and lung cancer: a systematic review.Cancer chemoprevention by dietary polyphenols: promising role for epigenetics.Chemopreventive and Anticancer Activities of Allium victorialis var. platyphyllum Extracts.A six-month crossover chemoprevention clinical trial of tea in smokers and non-smokers: methodological issues in a feasibility study.Polyphenols and the modulation of gene expression pathways: can we eat our way out of the danger of chronic disease?Role of retinoic acid in the modulation of benzo(a)pyrene-DNA adducts in human hepatoma cells: implications for cancer prevention Epigenetic targets of bioactive dietary components for cancer prevention and therapy.Interventions for treating oral leukoplakia to prevent oral cancer.Gene expression profiling predicts the development of oral cancer.Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells Tea and cancer prevention: epidemiological studies.Tea consumption and the risk of five major cancers: a dose-response meta-analysis of prospective studies.The BATTLE to personalize lung cancer prevention through reverse migration.Optimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials.The chemopreventive properties and therapeutic modulation of green tea polyphenols in oral squamous cell carcinoma.Targeting the epigenome with bioactive food components for cancer prevention High-throughput, quantitative analysis of acrolein-derived DNA adducts in human oral cells by immunohistochemistry.Epigenetic mechanisms in oral carcinogenesis.Protection of dietary polyphenols against oral cancer.Lessons learned from cancer prevention studies with nutrients and non-nutritive dietary constituents.Chemopreventive potential of natural compounds in head and neck cancer Natural products for cancer prevention Phytomedicine in otorhinolaryngology and pulmonology: clinical trials with herbal remedies.Going Green: The Role of the Green Tea Component EGCG in Chemoprevention.Cancer prevention by green tea: evidence from epidemiologic studies.Luteolin nanoparticle in chemoprevention: in vitro and in vivo anticancer activity.Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.

P2860

Q26823403-43F3E451-C50A-4D99-8438-484A41705D03 Q26824374-756DA6EA-49D3-40D2-80F5-AB426BCF5F91 Q27002456-B21FCCDE-D189-4932-8E2F-043D5A64BE69 Q27021094-12B05C36-8427-4E25-AC41-26DFAC1AD058 Q27693327-614A655F-2F3F-4BD5-9C28-11A197ADFC23 Q28076334-D2BF057B-725F-4A02-B316-B088DC98CA40 Q28079722-8BD7CB88-70C4-4879-A91D-944E04357DA0 Q28728905-A95D6304-58F3-4339-8119-F9698E829A22 Q29012696-7830E990-9D28-469F-9407-F3C7A17A2F00 Q30242061-B3AB69B7-5DE0-4AC2-ADEC-740867492B2B Q33567953-A7D65439-DDCF-4762-AC04-1EBF2A22A2CF Q33996334-47F3ECA3-F7CA-4208-A374-A7A3BE5A9B39 Q34251168-B32C7FAC-71AB-4C5E-BB95-580CEBFD6931 Q34270754-D83D41CF-13C7-4D11-99B3-41733F494600 Q34279875-05740321-6AD7-44CC-BAED-F97FB2863377 Q34305685-EB1D62A6-7107-40B3-9EF3-72901B402C75 Q34338778-85D5B469-531A-4BA1-99DA-021ED748DF00 Q34402471-DE59F0AB-F365-40C8-8D21-F61714FEDCCD Q34402493-072DCC66-F0C7-40A4-9C87-6E8EECB25DFA Q34508252-3A0F4495-4DCE-4822-8AC7-B04E3EBAE124 Q34535749-26C3F07C-AD6A-41F1-9507-8A512B4161FC Q34782013-222446E7-E287-4A54-83F0-592CDAD2AE7F Q34805329-495DF507-5AB0-4C93-94C7-76F9DF0C0805 Q35068711-C1A7D01A-2E63-4F97-B31E-AE7F452C6598 Q35122478-CB13B5F4-061B-4FCF-8F5D-1C75073754BE Q35208501-ABC4C0BB-60F0-4BB0-89E8-3093F757F34A Q35307851-C9F5B71B-56C1-4D45-8ADC-B957A7D34C2F Q35391881-44BABA25-0309-4149-AC20-D71861680B15 Q36072083-897FA581-FF27-4B49-90C8-81B83E835547 Q36473343-840407DF-AADF-4BCC-9882-63586091A242 Q36602726-9AC346B1-E945-44B3-A371-09D5BAC4BBCC Q37050854-7A41F738-B825-4B61-8D23-EDBCBD735D65 Q37067798-376390C1-FD9E-4BAE-AAFF-88BC101F9A40 Q37097045-1FB1A4EB-1582-41E0-96EC-D7F282564C73 Q37109727-9BEAB709-0BB9-4AFD-AC7D-8739D156BA01 Q37148776-6EE7F80D-F80A-4BEB-9728-5FB29B99D07A Q37198232-AFCDEE97-5FC9-41A0-8197-1E4EA2546FF3 Q37318414-B8230C0D-F267-4808-AA93-E3659E40E186 Q37466552-6B7FA53A-EF4F-4D24-969D-1FB70C1507B5 Q37517126-A0E5A3BD-39F0-4989-9448-C87305A34188

P2860

Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions

http://www.wikidata.org/entity/Q34568606

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase II randomized, placebo-c ...... risk oral premalignant lesions

@ast

Phase II randomized, placebo-c ...... risk oral premalignant lesions

@en

Phase II randomized, placebo-c ...... risk oral premalignant lesions

@nl

type

label

Phase II randomized, placebo-c ...... risk oral premalignant lesions

@ast

Phase II randomized, placebo-c ...... risk oral premalignant lesions

@en

Phase II randomized, placebo-c ...... risk oral premalignant lesions

@nl

prefLabel

Phase II randomized, placebo-c ...... risk oral premalignant lesions

@ast

Phase II randomized, placebo-c ...... risk oral premalignant lesions

@en

Phase II randomized, placebo-c ...... risk oral premalignant lesions

@nl

P1433

Q34568606-6F658585-F6B9-4017-93C1-8EE38D49147C

P1476

Q34568606-88165E6D-3910-49D9-B247-845100B4792B

P2093

Q34568606-08CD2C70-B16F-4CE1-9FA1-252806738530

Q34568606-1CF68737-4F93-4819-8948-3CFF0FE61240

Q34568606-36C6049E-4855-464D-B225-AAE62447E198

Q34568606-5D6FCEC5-7433-4726-83CA-63FFDD14D071

Q34568606-74A17F47-FA66-4D5B-87CF-8A6F033A440E

Q34568606-879E7D9F-4B1A-43CF-A94B-56835300B83F

Q34568606-9281F76F-B688-4A77-8475-71ED0589A651

Q34568606-AF8E0B16-167C-41EC-8903-29F01106DCF4

Q34568606-B378DF23-C0C2-49FF-81C8-BF26F00D3EA9

Q34568606-C9F50515-C444-4DF1-8DB2-3FF64E4E344F

P2860

Q34568606-068E2BF8-3FDA-4855-A81D-FA7C12E9981F

Q34568606-0799F244-06BD-465A-8053-44F2153A801E

Q34568606-0FD5A495-FFCF-4D08-8799-E45604DC18C5

Q34568606-12E3DE61-0814-4928-BAB1-A76F1F8DCE63

Q34568606-231C8E94-0932-44AD-B477-C76281E66AB0

Q34568606-25D50EDB-A4EF-40FC-8EAD-EC0C3CD1821C

Q34568606-263C382B-06F1-4167-8765-FB24B454EAAF

Q34568606-273036D6-37B7-4CEB-AB16-78A9A57F2050

Q34568606-2EEF597D-9A88-42AF-8144-DE6BED7A336B

Q34568606-36C3738C-E567-48E6-A64A-820572760B14

P304

Q34568606-C9FE7C3C-DB4B-45B1-9FF8-72AAFBC597EA

P31

Q34568606-1AEDA267-1771-4FF0-B037-70773F8B4BD3

P356

Q34568606-D485BAE3-5A77-41C6-AAC6-312EB5AF0DCF

P433

Q34568606-F8276430-BAB4-4265-9036-FED4E11D760B

P478

Q34568606-E6402C04-D4C1-41F0-B41A-7DBF2817E605

P50

Q34568606-07BEB769-E880-4A19-B456-4287BAC7CE4A

Q34568606-484EBDA6-375E-43BE-BEC5-1B4970F98F67

Q34568606-DEE08B8D-5157-4C37-93D8-7594604663B6

P577

Q34568606-E7222CA4-077D-4C2B-9AA3-9015225FEA0D

P698

Q34568606-AF437D9B-EC62-4C0F-9F79-0D3A300AB525

P921

Q34568606-260D321D-DEF1-4D4A-BA72-C84BD41D8CC0

Q34568606-628C9A87-1B85-4001-8D4A-223014A3091B

P932

Q34568606-4CE469C9-3682-4C47-9B49-A6A9BBA5C5E8

P356

1940-6207.CAPR-09-0121

P1433

Cancer Prevention Research

P1476

Phase II randomized, placebo-c ...... risk oral premalignant lesions

@en

P2093

Adel K El-Naggar

http://www.w3.org/2001/XMLSchema#string

Anne S Tsao

http://www.w3.org/2001/XMLSchema#string

Diane Liu

http://www.w3.org/2001/XMLSchema#string

J Jack Lee

http://www.w3.org/2001/XMLSchema#string

Jack Martin

http://www.w3.org/2001/XMLSchema#string

Kirk S Culotta

http://www.w3.org/2001/XMLSchema#string

Li Mao

http://www.w3.org/2001/XMLSchema#string

Waun K Hong

http://www.w3.org/2001/XMLSchema#string

Xi-ming Tang

http://www.w3.org/2001/XMLSchema#string

Yuko M Sagesaka

http://www.w3.org/2001/XMLSchema#string

P2860

Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia.

Mechanistic findings of green tea as cancer preventive for humans.

Epigallocatechin 3-gallate and green tea catechins: United they work, divided they fail

A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications.

Catechin metabolism: glutathione conjugate formation catalyzed by tyrosinase, peroxidase, and cytochrome p450.

13-cis-retinoic acid in the treatment of oral leukoplakia.

Cyclin D1 and cancer development in laryngeal premalignancy patients.

Pooled estimate of world leukoplakia prevalence: a systematic review.

P304

931-941

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1940-6207.CAPR-09-0121

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Ann Gillenwater

Ignacio I Wistuba

Vassiliki Papadimitrakopoulou

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19892663

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4243312

http://www.w3.org/2001/XMLSchema#string